%0 Case Reports
%T A rare adverse effect in inebilizumab therapy for neuromyelitis optica spectrum disorder: a case report.
%A Chen X
%A Shi Z
%A Wang R
%A Zhou H
%J Ther Adv Neurol Disord
%V 17
%N 0
%D 2024
%M 39072007
%F 6.43
%R 10.1177/17562864241258787
%X Inebilizumab is one of the monoclonal antibodies approved as maintenance therapy for aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (NMOSD). It is a humanized monoclonal antibody targeting cluster of differentiation 19 (CD19). Common adverse reactions include urinary tract infections, nasopharyngitis, arthralgia, infusion reactions, headaches and a decrease in immunoglobulin levels. Here, we present a case of an NMOSD patient who experienced transient hyperCKaemia after the use of inebilizumab. The adverse reactions of this very rare monoclonal antibody drug improved after discontinuation.